REVIEW ARTICLE

CRISPR/CAS9 And Gene Editing in Drug Delivery: Emerging Delivery Systems for Gene Therapy and Genome

Patil G R*, Varma S K

Datta Meghe Institute of Higher Education and Research, Wardha, India

Received: 30th Nov, 2024; Revised: 8th Jan, 2024; Accepted: 21st Feb, 2024; Available Online: 25th Mar, 2025

ABSTRACT

GENETIC EDITING: CRISPR/Cas9 technologies have revolutionised genome editing. They offer unmatched precision, speed, and versatility. Familiar with the immune system of bacteria, it is now a powerful tool. It treats genetic diseases, infectious diseases, and cancer. And even as an omen, its clinical effectiveness demands reliable, precise means of administration. These systems have created viral and non-viral platforms. The list includes: lipid nanoparticles (LNPs), viral vectors (AAVs), and polymeric nanoparticles. New delivery technologies, like SORT LNPs and VLPs, have improved targeting. They offer better therapy and fewer off-target effects.Nonetheless, significant obstacles remain. Delivery efficiencies, immunogenicity and scalability are huge hurdles to wide-scale clinical deployment. To reduce these difficulties, we can develop small Cas variants like Cas12a. We can also engineer guide RNAs (gRNAs) for better precision and fewer off-target effects. There are promising prospects. They come from AI-optimised, hybrid delivery platforms. They are virally-free and non-viral. The FDA's approval of CRISPR drugs for sickle cell disease shows their potential to cure some incurable diseases. Trials now include rare genetic diseases, cancers and metabolic disorders. No matter how big it is, production scale and cost are a bottleneck. We still need better manufacturing and quality control practices. This review examines the latest advances in CRISPR/Cas9 delivery methods. It covers the barriers to clinical use and the future of this groundbreaking technology. CRISPR/Cas9 could revolutionise medicine. It may provide treatments that target the root causes of diseases. It could overcome current limits and use new discoveries.

Keywords: CRISPR/Cas9, gene editing, drug delivery, lipid nanoparticles, gene therapy, genome editing, viral vectors

How to cite this article: Patil G R, Varma S K. CRISPR/CAS9 And Gene Editing in Drug Delivery: Emerging Delivery Systems for Gene Therapy and Genome. International Journal of Drug Delivery Technology. 2025;15(1):335-41. doi: 10.25258/ijddt.15.1.46

Source of support: Nil

Conflict of interest: None

INTRODUCTION

The CRISPR/Cas9 system has revolutionised genome editing. It is based on bacterial immunity. Its accuracy, effectiveness, and flexibility are unmatched. Its uses go beyond genetic engineering. Most notably, in drug delivery. It has great promise for treating infectious diseases, genetic disorders, and most cancers. It allows targeted genome editing, allowing for new therapeutics that go right to the source of many diseases, not their symptoms.

Latest Advances in CRISPR/Cas9 Delivery Mechanisms

Effective, accurate delivery mechanisms are essential for the success of CRISPR/Cas9. Recent improvements in delivery systems aim to fix issues. These include off-target effects, immune responses, and limited tissue targeting. A variety of promising strategies encompass

Viral Vectors

Lentiviruses and adeno-associated viruses (AAV) are preferred for delivering CRISPR components. They are effective at integrating genetic material into cells. However, safety issues, like immunogenicity and limited packaging, need work.[1.2]

Non-Viral Systems: Non-viral methods, like lipid nanoparticles (LNPs) and polymers, are now more popular.. They have less immunogenicity and are scalable. These methods can efficiently deliver RNA, DNA, or protein variants of CRISPR/Cas9. They avoid insertional mutagenesis.[3]

Physical Methods

Techniques like electroporation and microinjection directly introduce CRISPR components into target cells. These methods are very accurate. But, they are sometimes limited to ex vivo use due to their intrusive nature..[4.5]

Cell-Specific Targeting

Better cell-specific delivery has improved accuracy. This includes using antibodies or peptides to conjugate with CRISPR/Cas9 systems. It targets specific cell types, reducing off-target effects and boosting therapeutic efficacy.[6]

Overcoming Challenges in Clinical Implementation

Despite these advancements, obstacles remain in using CRISPR/Cas9 therapies in medicine. The following domains need focused study: Mitigating Off-Target Effects. We must reduce unwanted changes. Advanced gRNA design algorithms and modified Cas proteins are vital for this. This includes high-fidelity variants. immuno Evasion: Researchers are studying ways to reduce immune responses. These include the temporary production of Cas proteins and immune-modulating therapies. Scalability and Economic Efficiency: Complex delivery systems often

**Author for Correspondence: gayatrip265@gmail.com, varmasushil9@gmail.com*



Figure 1: CRISPR/Cas9 Delivery Systems: An Overview of Viral, Non-Viral, and Physical Approaches

Figure 2: Key Challenges and Innovations in CRISPR/Cas9 Delivery

raise production costs. To improve accessibility, we must optimize production and enforce strict quality controls.[7]

METHODOLOGY

The search method used key terms like "CRISPR/Cas9," "gene delivery," "lipid nanoparticles," "viral vectors," and "gene therapy." It focused on studies published from 2018 to 2024. This ensured the incorporation of the latest breakthroughs in the field. The review focused on peer-reviewed academic papers, clinical trials, and detailed reviews. They provided deep analyses of various delivery systems for CRISPR/Cas9 technology. The analysis aimed to summarise, comprehensively and up-to-date, the trends in gene-editing research. It did this by establishing these criteria.

Advancements in CRISPR/Cas9 Delivery Systems

Lipid Nanoparticles (LNPs)

Lipid nanoparticles (LNPs) are key to developing non-viral delivery systems for CRISPR/Cas9. They are highly adaptable and effective. These nanoparticles can encapsulate many types of nucleic acids, like DNA and RNA. They protect them from degradation and enable their transport into target cells.[8] These attributes have made LNPs a top choice. This is true for in vivo gene-editing applications where safety is crucial. LNPs protect their genetic payload during transit in the bloodstream. They ensure it is intact upon arrival at the target site. They do this by using their ability to be absorbed by cells. Upon entering the cells, these nanoparticles quickly release their contents into the cytoplasm. This allows the CRISPR/Cas9 system to edit genes accurately. Recently, there have been many breakthroughs in LNP design. Selective Organ Targeting (SORT) LNPs are among the most revolutionary. SORT LNPs improve delivery by using specialized lipids or targeting ligands. This achieves organ-specific accuracy. This strategy improves therapy and lowers the risk of off-target effects. It is a big advance in gene therapy.[9]

Also, LNPs have key practical benefits. They are highly biocompatible and scalable for clinical use. So, they suit many therapeutic areas. LNPs are vital in modern medicine. They treat rare genetic disorders, cancers, and infections. With ongoing breakthroughs, these nanoparticles will transform CRISPR/Cas9 therapies. This will advance precision medicine towards wider clinical use.

Viral Vectors

Viral vectors, like adeno-associated viruses (AAVs) and lentiviruses, excel at delivering CRISPR/Cas9. These vectors can efficiently deliver genes. They are ideal for uses needing long-term, consistent expression of therapeutic genes. Each vector type has unique benefits. They suit specific contexts in gene-editing research and clinical applications.[10]

Adeno-associated viruses (AAVs) are preferred for their low immunogenicity. They can also target certain tissues precisely. These traits make them ideal for in vivo use. There, it is crucial to reduce immune responses and improve selectivity. The limited cargo capacity of AAVs is a big problem. The CRISPR/Cas9 apparatus, especially larger Cas proteins, often exceeds this limit. Notwithstanding these constraints, current engineering initiatives are mitigating these limitations. Researchers are creating new AAV serotypes and optimized constructs. They aim to improve the packaging of CRISPR/Cas9 components. This includes compact Cas protein variants and split-Cas systems. They can be reassembled in target cells.[11]

Lentiviruses can package more than AAVs. This makes them better for delivering larger or multiple genetic payloads. These vectors incorporate into the host genome. This allows stable expression of the CRISPR/Cas9 system. It's especially useful for applications that require long-lasting gene-editing activity. Nonetheless, their integration potential requires meticulous evaluation of insertional mutagenesis hazards. Improvements in vector design have greatly improved their safety. These include self-inactivating lentiviral vectors and tissue-specific promoters.[12]

As the field progresses, we must enhance viral vector technology. It is key to the efficacy of CRISPR/Cas9

Table 1. Challenges and Future Directions in CRISPR/Cas9 Technology

Challenge	Description	Future Directions
Delivery Efficiency	Difficulty in achieving precise delivery to target tissues.	Hybrid delivery systems, ligand-based targeting, SORT nanoparticles.
Off-Target Effects	Risk of unintended genetic modifications affecting safety and efficacy.	Enhanced gRNA design, high-fidelity Cas variants like eSpCas9 and HiFi Cas9.
Immunogenicity	Immune responses to Cas proteins and delivery vectors.	Transient Cas expression, immune-suppressive regimens, engineered low-immunogenic Cas.
Scalability	High cost and complexity of manufacturing delivery systems, especially viral vectors.	Scalable bioreactors, non-viral alternatives, automated production processes.
Combination Therapies	Challenges in integrating CRISPR with other treatments (e.g., immunotherapy).	CRISPR-modified CAR-T cells, personalized combination therapies.
Regulatory Hurdles	Ensuring safety, efficacy, and consistency in clinical applications.	Streamlined guidelines, long-term clinical trials, and monitoring systems.

Table 2. Summary of CRISPR/Cas9 Delivery Systems and Challenges

Method/System	Advantages	Challenges	Innovations
Viral Vectors	High efficiency, stable expression (lentivirus), low immunogenicity (AAV).	Limited cargo (AAV), immunogenicity.	Self-inactivating lentivirus, novel AAVs.
Non-Viral Systems	Biocompatibility, scalable.	Lower delivery efficiency, stability issues.	SORT LNPs, PLGA, chitosan.
Virus-Like Particles	Precision, low immunogenicity.	Cargo loading, stability.	Customizable VLPs.
Physical Methods	High precision (ex vivo).	Invasive, limited in vivo use.	Electroporation in cell engineering.
Targeted Delivery	Tissue- and cell-specific targeting.	Complex design, variable receptor expression.	SORT LNPs, antibody-conjugates.

therapeutics. These vectors can address current obstacles and create novel solutions. They could enable the fast, secure delivery of gene-editing tools for many diseases and therapies

Virus-Like Particles (VLPs)

Viral-like particles (VLPs) are a major advancement in gene delivery. They combine aspects of viral and non-viral methods. Structurally, VLPs resemble viruses but lack their genetic material. This makes them safer, ideal for delivering CRISPR/Cas9 components. VLPs can carry various gene-editing tools, such as plasmid DNA, mRNA, or ribonucleoproteins. They mimic viral infection processes, ensuring efficient entry into target cells.[13] This method rivals traditional viral vectors. So, VLPs are better for precise delivery with a low immune response. Recent engineering improvements have enhanced VLPs' performance and flexibility. Scientists can now modify their surfaces with specific proteins, allowing for targeted delivery. This boosts treatment effectiveness and reduces side effects.[14] VLPs can also be tailored to interact with specific cell types or conditions. They blend the efficiency of viral systems with the safety and adaptability of non-viral ones. VLPs avoid problems with viral DNA integration. They also avoid the challenges of producing non-viral systems, like lipid nanoparticles. They are suitable for targeted treatments of genetic disorders and new cancer therapies.[15] As research progresses, VLPs are expected to improve. They will have better capacity, targeting, and stability. They will play a key role in the future of CRISPR/Cas9 delivery systems. They will combine the best features of existing methods and fix their drawbacks.[16]

Polymeric Nanoparticles

Polymeric nanoparticles are popular for delivering CRISPR/Cas9 components. Made from synthetic or natural polymers, they offer key benefits in gene editing. Their stability protects CRISPR/Cas9 components like plasmid DNA, mRNA, or RNPs during storage and transport. They also allow controlled release of genetic material. Researchers can adjust the polymer's properties to control release timing and methods. This can improve treatment effectiveness and reduce side effects.[17,18]

Recent advances in biodegradable polymers, like PLGA and chitosan, have improved these nanoparticles. These materials are biocompatible and break down safely, minimizing immune responses. This makes them ideal for in vivo use. Moreover, nanoparticles can be modified for better performance. Adding targeting ligands or peptides improves delivery efficiency, reducing off-target effects. They can also be designed to protect genetic material from breakdown. This would improve their effectiveness.[19]

Polymeric nanoparticles are adaptable in size, shape, and composition. This makes them suitable for various therapies. They are key in treating genetic disorders, chronic diseases, and cancer. Ongoing research aims to

improve their targeting, efficiency, and scalability. This ensures their vital role in future gene-editing technologies.[20]

Current Trends and Challenges

Novel Developments in CRISPR/Cas9 Technology CRISPR/Cas9 gene editing is advancing rapidly. Many key factors are expanding its range of applications. These trends are addressing key issues with gene-editing tech. They are also opening new paths for therapy.

Targeted Delivery

Advancements in nanoparticle manufacturing and ligand conjugation have greatly improved CRISPR/Cas9 delivery. Researchers have made delivery systems that target very selectively. They added ligands that bind to specific receptors on the target tissues or cell types. This tissue- and cell-specific targeting reduces off-target effects. It improves the therapeutic index and boosts the safety of gene-editing medicines. Innovations like SORT nanoparticles and modified viral-like particles (VLPs) are leading these efforts. They enable targeted delivery to organs like the liver, lungs, or central nervous system, based on therapeutic need.[21, 22]

Minimizing Off-Target Effects

A major problem with gene editing is the risk of unintended changes to genes. These changes may have harmful effects or reduce the therapy's effectiveness. Researchers have focused on creating advanced Cas9 variants. These include high-fidelity (HiFi) Cas9 and enhanced specificity Cas9 (eSpCas9). They have less off-target cleavage but maintain editing efficiency. Moreover, the fabrication of improved guide RNAs (gRNAs) has significantly reduced off-target activity. These gains ensure CRISPR/Cas9 systems make accurate cuts at specific genomic sites. This enhances their safety for therapy.[23]

Combination Therapies

The combination of CRISPR/Cas9 with other therapies is expanding its medical use. For example, it shows promise in treating cancers and autoimmune diseases when used with immunotherapy. Gene editing can boost T-cell therapies, like CAR-T cells. It does this by enhancing their ability to find and attack cancer cells or by overcoming immune barriers. Moreover, CRISPR is being explored to improve traditional drug treatments. This could lead to personalised therapies based on a person's genetics. Such combined approaches might offer better results than single therapies. They provide more comprehensive and effective treatment options. The development of CRISPR/Cas9 has made it more precise, safer, and more applicable in therapies. Innovations like targeted delivery systems and new molecular tools are key. These advancements are pushing the boundaries of medicine. They not only solve current problems but also widen the scope of CRISPR/Cas9 applications. This progress is steering us towards a future where gene editing is central to personalised healthcare.[24.25]

Challenges in the Implementation of CRISPR/Cas9 Technologies

CRISPR/Cas9 is a major breakthrough in gene editing. However, it faces significant challenges for practical use. These challenges need solving to unlock its full potential and make it widely available in therapies. Key issues include delivery efficiency, immune reactions, and scalability. Each poses unique problems that researchers are working to tackle.1. Delivery Efficiency

Delivery Efficiency

A key hurdle in CRISPR/Cas9 therapy is delivering the editing tools to target tissues. It must be both effective and accurate. This is vital for treating systemic disorders. Genetic material must access several organs or widely spread cells. Delivery technologies, like lipid nanoparticles (LNPs) and viral vectors, have limits. So do polymeric nanoparticles. They struggle with tissue penetration, cellular uptake, and delivery efficacy. Viral vectors like adeno-associated viruses (AAVs) are very efficient at transducing cells. However, their limited cargo capacity and tissue tropism are major drawbacks. Non-viral technologies, albeit safer, frequently encounter low delivery rates in vivo. Researchers are investigating novel techniques to improve therapies. They include tailored delivery systems that use tissue-specific ligands or advanced nanotechnology. [26]

Immunogenicity

CRISPR/Cas9 therapeutics face safety issues from immune responses. Delivery methods, like viral particles, can trigger these responses. So can Cas proteins, which are from bacteria. Such immune reactions may reduce treatment effectiveness or cause harmful side effects. To reduce these risks, researchers are exploring less immunogenic Cas9 variants. They are also testing temporary expression systems. They also consider using immunosuppressive drugs during treatment. Also, they are testing non-viral methods, like polymeric nanoparticles and exosomes. They have lower immunogenicity than viral vectors.[27]

Scalability

The difficulty of producing delivery systems, especially viral vectors, at a clinical scale hampers the wide use of CRISPR/Cas9 therapies. Viral vectors like AAVs and lentiviruses require complex, costly, and labor-intensive processes. This limits their availability. Moreover, it's tough to ensure batch consistency in mass production while keeping high purity and quality. Non-viral methods, though easier to scale, struggle with consistency and efficiency. Researchers and biotech companies are developing advanced technologies to address these challenges. These include automated systems, scalable bioreactors, and new purification methods. They are also exploring hybrid platforms. These would combine the strengths of both viral and non-viral systems for scalable solutions.[28]

Future Directions in CRISPR/Cas9 Research and Development

As CRISPR/Cas9 technology advances, researchers seek new ways to overcome its limits and unlock its full potential. The new initiatives include: 1. Improved Cas systems. 2. Hybrid delivery methods. 3. AI-driven innovations. Together, these new technologies will transform gene editing. They will make it more precise, efficient, and accessible.

Engineered Cas Systems

A key problem in CRISPR/Cas9 therapies is delivering large genetic material to target cells. Scientists are working to create compact, efficient Cas versions to fix this. Cas12a (Cpf1) and CasX are smaller than Cas9. They are easier to

fit into delivery vectors with limited capacity, like adeno-associated viruses (AAVs). These modified Cas systems remove delivery size limits. They also have unique benefits. They include specific PAM recognition sites and better precision in some genomic contexts. Also, smaller, more flexible Cas proteins could expand CRISPR's reach. Efforts to create them, especially for specific therapies, are underway.[29]

Hybrid Delivery Systems

Hybrid delivery methods combine viral and non-viral vectors. This approach boosts efficiency and reduces risks. For instance, a viral vector might be used for its high transduction efficiency. Meanwhile, lipid nanoparticles (LNPs) could be added for their compatibility and scalability. This combo boosts gene editing success. It also cuts the risk of immune reactions and off-target effects. Hybrid systems are ideal for complex therapies where traditional methods fall short. They offer a flexible solution to the challenges of in vivo gene editing.[30]

Artificial Intelligence

AI is swiftly revolutionizing CRISPR/Cas9 research. It is enabling unmatched precision and efficiency. AI-powered algorithms improve the design of guide RNAs (gRNAs). They ensure precise targeting of intended genomic sites with minimal off-target effects. These algorithms analyse large datasets to find patterns. They predict the best gRNA sequences for specific tasks. AI is used to improve delivery tactics, in addition to gRNA optimization. It helps researchers find the best vectors and methods for therapies. AI's use in gene editing speeds up development. It also makes CRISPR/Cas9 therapies more reliable and safe.[31]

Clinical Translation of CRISPR/Cas9 Therapies

The shift from lab research to clinical use is vital for CRISPR/Cas9 technology. Efforts are ramping up to turn these gene-editing tools into therapies for various diseases. Recent progress shows their effectiveness, especially in treating complex genetic disorders. A key milestone was the FDA's approval of CRISPR therapies for sickle cell disease. This highlights CRISPR/Cas9's potential in treating previously incurable genetic diseases. These therapies have improved patients' lives by fixing the genes that cause sickle cell disease. This success suggests CRISPR/Cas9 could be a safe and effective treatment for other genetic disorders. Now, more trials are underway, exploring CRISPR-based treatments for conditions like Duchenne muscular dystrophy, Huntington's disease, cancer, and diabetes. Early results are promising, showing effective gene editing and health benefits. In cancer treatment, CRISPR-modified immune cells are being tested to better target tumors. Similarly, CRISPR/Cas9 is being used to fix genes in metabolic disorders, aiming for long-term solutions rather than just symptom relief. However, moving CRISPR/Cas9 to clinical use faces major challenges. Researchers are working on better delivery methods, reducing side effects, and scaling production. Collaboration among scientists, businesses, and regulators is key to overcoming these hurdles, ensuring a safe and effective transition from research to approved treatments.[32, 33]

CONCLUSION

The introduction of the CRISPR/Cas9 technology has been a major milestone in the areas of medicine and genome editing, revolutionizing the way researchers and doctors treat genetic and complex diseases. The tool's unparalleled accuracy in identifying and changing specific DNA sequences has paved the way for the treatment of diseases that were previously unthinkable to cure. During the previous decade, the technology has undergone a real transformation, especially in the creation of advanced delivery systems which are designed to carry CRISPR/Cas9 components effectively to target cells.

However, in spite of the fact that these innovations are being made, several main issues are still the things that don’t let CRISPR/Cas9 fully realize its therapeutic potential. One of the main problems is the delivery efficiency. It is very important to have precise and reliable delivery approaches to specific tissues and cell types in order to be successful therapeutically, but current delivery systems, like lipid nanoparticles (LNPs), viral vectors, and polymer-based systems, frequently encounter problems like poor cellular uptake, unintended off-target effects, and insufficient biodistribution. To master these drawbacks, new approaches should be devised, for instance, hybrid delivery systems that marry viral and non-viral technologies or the invention of new materials that only aim at the desired tissue are the best solutions.

A major roadblock is immunogenicity. Where the immune response to CRISPR/Cas9 components (particularly bacterial Cas proteins and vectors) can reduce therapeutic efficacy and create safety issues for this kind of therapy. Efforts are underway to mitigate these risks by improving the immunogenicity of Cas protein variants, engineering systems that are able to transiently express gene-editing complexes and investigating non-viral delivery routes. Such approaches are needed to make sure that gene-editing therapies are delivered safely and repeatedly without invoking unwanted immune responses.

Scalability is yet another big challenge on top of this. As the field of CRISPR-based therapeutics move from bench to bedside, scalable production approaches for delivery systems, particularly scalable viral vectors (e.g. adeno-associated viruses AAVs) become essential. Processes need to be developed and optimized for large scale clinical manufacture of high quality 'normal' materials that are reproducible and affordable. Enhancements to bioprocessing technologies and new delivery platforms (eg synthetic nanoparticles & exosome-based) provide ways to circumvent these scalability problems.

REFERENCES

1. Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, Zhang H. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Advanced drug delivery reviews. 2021 Sep 1;176:113891.
2. Yang W, Yan J, Zhuang P, Ding T, Chen Y, Zhang Y, Zhang H, Cui W. Progress of delivery methods for CRISPR-Cas9. Expert opinion on drug delivery. 2022 Aug 3;19(8):913-26.
3. Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic

applications. Journal of controlled release. 2017 Nov 28;266:17-26.
4. Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. Journal of controlled release. 2017 Nov 28;266:17-26.
5. Chen F, Alphonse M, Liu Q. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2020 May;12(3):e1609.
6. Zhou L, Yao S. Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications. Molecular Biomedicine. 2023 Apr 7;4(1):10.
7. Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. American Society of Clinical Oncology Educational Book. 2013 Jan 1;33(1):118-25.
8. Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, Schubert MS, Friedmann-Morvinski D, Cohen ZR, Behlke MA, Lieberman J. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science advances. 2020 Nov 18;6(47):eabc9450.
9. Han JP, Kim M, Choi BS, Lee JH, Lee GS, Jeong M, Lee Y, Kim EA, Oh HK, Go N, Lee H. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Science advances. 2022 Jan 21;8(3):eabj6901.
10. Asmamaw Mengstie M. Viral vectors for the in vivo delivery of CRISPR components: advances and challenges. Frontiers in Bioengineering and Biotechnology. 2022 May 12;10:895713.
11. Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024 Jan 6:105338.
12. Caprifico AE, Foot PJ, Polycarpou E, Calabrese G. Advances in chitosan-based CRISPR/Cas9 delivery systems. Pharmaceutics. 2022 Sep 1;14(9):1840.
13. Lyu P, Lu B. New advances in using virus-like particles and related technologies for eukaryotic genome editing delivery. International Journal of Molecular Sciences. 2022 Aug 6;23(15):8750.
14. Ikwuagwu B, Tullman-Ercek D. Virus-like particles for drug delivery: a review of methods and applications. Current Opinion in Biotechnology. 2022 Dec 1;78:102785.
15. Wichmann M, Maire CL, Nuppenau N, Habiballa M, Uhde A, Kolbe K, Schröder T, Lamszus K, Fehse B, Głów D. Deep Characterization and Comparison of Different Retrovirus-like Particles Preloaded with CRISPR/Cas9 RNPs. International Journal of Molecular Sciences. 2023 Jul 13;24(14):11399.
16. Tan X. Gag-derived VLPs and the delivery of CRISPR-Cas9 system in Gene and Cell Therapies. Highlights in Science, Engineering and Technology. 2023 Mar 21;36:1511-6.
17. Chen K, Jiang S, Hong Y, Li Z, Wu YL, Wu C. Cationic polymeric nanoformulation: Recent advances in material design for CRISPR/Cas9 gene therapy. Progress in Natural Science: Materials International. 2019 Dec 1;29(6):617-27.
18. Verma R, Sahu R, Singh DD, Egbo TE. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections. InSeminars in cell & developmental biology 2019 Dec 1 (Vol. 96, pp. 44-52). Academic Press.
19. Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024 Jan 6:105338.
20. Kim M, Hwang Y, Lim S, Jang HK, Kim HO. Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9. Pharmaceutics. 2024 Sep 11;16(9):1197.
21. Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024 Jan 6:105338.
22. Singh D. Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies. AAPS PharmSciTech. 2024 Jun 6;25(5):129.
23. Naeem M, Majeed S, Hoque MZ, Ahmad I. Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. Cells. 2020 Jul 2;9(7):1608.
24. Bhattacharjee R, Jana A, Nandi A, Sinha A, Bhattacharjee A, Mitra S, Kar S, Dey A, Singh SK, Varma RS, Panda PK. Synergy of nanocarriers with CRISPR-Cas9 in an emerging technology platform for biomedical appliances: Current insights and perspectives. Materials & Design. 2022 Dec 1;224:111415.
25. Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: a new and promising player in gene therapy. Journal of medical genetics. 2015 May 1;52(5):289-96.
26. Aljabali AA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology. 2024 Jan 6:105338.
27. Wang L, Chen Y, Liu X, Li Z, Dai X. The application of CRISPR/Cas9 technology for cancer immunotherapy: Current status and problems. Frontiers in Oncology. 2022 Jan 17;11:704999.
28. Bhowmik P, Konkin D, Polowick P, Hodgins CL, Subedi M, Xiang D, Yu B, Patterson N, Rajagopalan N, Babic V, Ro DK. CRISPR/Cas9 gene editing in legume crops: Opportunities and challenges. Legume Science. 2021 Sep;3(3):e96.
29. Nidhi S, Anand U, Oleksak P, Tripathi P, Lal JA, Thomas G, Kuca K, Tripathi V. Novel CRISPR–Cas

systems: an updated review of the current achievements, applications, and future research perspectives. International journal of molecular sciences. 2021 Mar 24;22(7):3327.
30. Chen Y, Ping Y. Development of CRISPR/Cas delivery systems for in vivo precision genome editing. Accounts of Chemical Research. 2023 Aug 1;56(16):2185-96.
31. Bhat AA, Nisar S, Mukherjee S, Saha N, Yarravarapu N, Lone SN, Masoodi T, Chauhan R, Maacha S, Bagga P, Dhawan P. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics. Journal of translational medicine. 2022 Nov 18;20(1):534.
32. Foley RA, Sims RA, Duggan EC, Olmedo JK, Ma R, Jonas SJ. Delivering the CRISPR/Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation. Frontiers in Bioengineering and Biotechnology. 2022 Sep 26;10:973326.
33. Luther DC, Lee YW, Nagaraj H, Scaletti F, Rotello VM. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Expert opinion on drug delivery. 2018 Sep 2;15(9):905-13.